What is the price target for IKT stock?
12 analysts have analysed IKT and the average price target is 5.87 USD. This implies a price increase of 211.97% is expected in the next year compared to the current price of 1.88.
INHIBIKASE THERAPEUTICS INC (IKT) Forecast, Price Target & Analyst Ratings
NASDAQ:IKT • US45719W2052
Current stock price
1.88 USD
-0.05 (-2.59%)
At close:
1.88 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INHIBIKASE THERAPEUTICS INC (IKT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.10
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.87
Upside
+ 211.97%
From current price of $1.88 to mean target of $5.87, Based on 12 analyst forecasts
Low
$3.03
Median
$5.61
High
$8.40
Price Target Revisions
1 Month
-4.17%
3 Months
-4.17%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for IKT. The average price target is 5.87 USD. This implies a price increase of 211.97% is expected in the next year compared to the current price of 1.88.
The average price target has been revised downward by 4.17% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
IKT was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IKT.
In the previous month the buy percentage consensus was at a similar level.
IKT was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Ladenburg Thalmann | Initiate | Buy |
| 2026-01-21 | B of A Securities | Initiate | Buy |
| 2025-12-11 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-12 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-08 | Jefferies | Initiate | Buy |
| 2024-10-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-18 | HC Wainwright & Co. | Initiate | Buy |
| 2022-11-16 | JonesTrading | Downgrade | Buy -> Hold |
| 2021-07-15 | JonesTrading | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.10
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 42.03%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
8.99%
Next Earnings Summary
IKT is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.1 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.1M 342.86% | 120K -96.13% | 260.5K 117.08% | -100.00% | 252.5K | 252.5K | 22.263M 8,717.03% | 83.295M 274.14% | 153.94M 84.81% | 255.94M 66.26% | 359.95M 40.64% | 468.21M 30.08% | ||
| EBITDA YoY % growth | N/A | -18.12M | -19.912M -9.89% | N/A -43.44% | -51.106M -78.93% | -53.772M -5.22% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -14.77M -423.76% | -18.13M -22.75% | -20.09M -10.81% | -22.086M -42.31% | -52.457M -83.49% | -69.451M -32.40% | -81.182M -16.89% | N/A | -32.303M | 43.682M 235.23% | 195M 346.41% | 329.89M 69.17% | 424.98M 28.82% | |
| Operating Margin | -476.45% | -15,108.33% | -7,712.02% | N/A | N/A | -27,505.45% | -32,151.32% | N/A | -38.78% | 28.38% | 76.19% | 91.65% | 90.77% | |
| EPS YoY % growth | N/A | -4.32 8.61% | -3.57 17.36% | -0.91 28.85% | -0.50 80.31% | -0.50 -0.07% | -0.56 -11.89% | -0.51 8.71% | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.10 42.03% | -0.11 3.07% | -0.11 11.66% | -0.11 -27.29% | -0.15 -50.32% | -0.14 -35.77% | -0.15 -28.99% | -0.15 -29.30% |
| Revenue Q2Q % growth | 288.567K | -100.00% | ||||||
| EBITDA Q2Q % growth | -12.686M -76.55% | -13.433M -24.43% | -14.039M -10.47% | -14.14M -12.81% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.971M -107.99% | -16.259M -50.10% | -17.65M -38.23% | -19.089M -41.21% | -23.187M -54.88% | -24.301M -49.46% | -26.578M -50.58% | -27.692M -45.07% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-0.73%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
INHIBIKASE THERAPEUTICS INC / IKT Forecast FAQ
When does INHIBIKASE THERAPEUTICS INC (IKT) report earnings?
INHIBIKASE THERAPEUTICS INC (IKT) will report earnings on 2026-05-12.
What are the consensus estimates for INHIBIKASE THERAPEUTICS INC (IKT) next earnings?
The consensus EPS estimate for the next earnings of INHIBIKASE THERAPEUTICS INC (IKT) is -0.1 USD and the consensus revenue estimate is 0 USD.